Fonar Press Releases

For Immediate Release

The Inventor of MR Scanning™

An ISO 9001 Company

Contact: Daniel Culver

110 Marcus Drive

Director of Communications

Melville, NY 11747-4292

Web site: www.fonar.com

Phone: (631) 694-2929

Email: investor @ fonar. com

Fax: (631) 390-1709


FONAR Announces Results of the Third Fiscal Quarter 2009 As Net Income Soars Past $1 Million for Nine Month Period

MELVILLE, NEW YORK, May 19, 2009 - FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, today announced its earnings for the third quarter of fiscal 2009 ending March 31, 2009. Net income for the nine month period ending March 31, 2009 was $1.1 million as compared to the nine month period one year earlier when there was a net loss of $6.7 million. For the third fiscal quarter ending March 31, 2009, the Company reported net income of $730,000 as compared to the same period one year earlier when it had a loss of $2.7 million.

Revenues increased 7.0% to $29.3 million for the nine month period ending March 31, 2009 as compared to $27.4 million for the nine month period ending March 31, 2008. For the quarter ending March 31, 2009, revenues increased 39.5% to $11.3 million as compared to $8.1 million for the quarter ending March 31, 2008.

Raymond Damadian, M.D., president and chairman of FONAR Corporation said, “We are delighted that the Company has once again become profitable. In fact we now have two straight quarters of income greater than $700,000. There are several reasons for this. While 2008 was a difficult year, we initiated an aggressive cost-cutting program. Costs and expenses have been reduced in most categories but most significantly in our selling, general and administrative expenses (S, G & A). Overall, S, G & A was reduced 36.0% from $15.5 million for the nine months ending March 31, 2008 to $10.0 million for the most current nine month period.”

Dr. Damadian continued, “Another reason is a refreshed focus on ‘selling scans’ through our UPRIGHT® Multi-Position™ MRI managed sites. We currently have nine UPRIGHT® MRIs and one older FONAR QUAD™ MRI being managed by HMCA (Health Management Corporation of America), FONAR’s wholly-owned subsidiary (www.hmca.com). There are UPRIGHT® MRI centers that scan more than 500 patients per month and we would like that to happen pervasively within the HMCA network.”

“We often find that the busier UPRIGHT® Multi-Position MRI centers are in an area with many single-position, recumbent-only competitor MRIs around them,” continued Dr. Damadian. “They will energize the local imaging market. When claustrophobic patients find out about the UPRIGHT® MRI, they will demand it from their referring physicians. Patients and the referring physicians seeking spine care will also seek out the best diagnostic device for their condition. Add advantages of scanning overweight patients, patients who can’t lie down, weight-bearing imaging of men and women with pelvic floor dysfunction, patients with scoliosis and the ability to perform high quality routine imaging of other body parts, and you have the opportunity for a very busy MRI site.”

As of March 31, 2009, there were 133 FONAR UPRIGHT® Multi-Position™ MRI units installed worldwide. During the third quarter of fiscal 2009 total product sales increased dramatically by 162.2 % to $6.2 million from $2.3 million over the corresponding quarter one year earlier.

During the third fiscal quarter of 2009, FONAR announced it has sold two UPRIGHT® Multi-Position™ MRI scanners to Doshi Diagnostic Imaging Services, P.C., which is among the country’s largest privately held multi-modality imaging companies, as well as the largest radiology group in New York. Doshi Diagnostic is headquartered in Bethpage, Long Island, and operates approximately 40 centers in Florida, New Jersey, Long Island, and New York City.

Another sale of an UPRIGHT® Multi-Position™ MRI was to the Tripoli Medical Center, a leading state-of-the-art medical center in Libya with approximately 1450 beds, 1000 physicians, and 3000 employees. This is an especially significant sale for FONAR, because it marks the entrance of the company’s UPRIGHT® imaging technology into the markets of Africa and the Middle East.

Also during the third fiscal quarter of 2009 Raymond Damadian, M.D. became the recipient of the 2009 AIMBE (American Institute for Medical and Biological Engineering) Honorary Fellow Award for his discovery of MRI. Dr. Damadian is the originator of the concept of magnetic resonance (MR) scanning of the human body (1969). The AIMBE Award was presented at the annual meeting of AIMBE, held February 11-13 in Washington, D.C.

The award says: “In 1970, Raymond Damadian, M.D., made the discovery that is the basis for magnetic resonance (MR) scanning that there is a marked difference in relaxation times between normal and abnormal tissues of the same type, as well as between different types of normal tissues. This seminal discovery, which remains the basis for the making of every MRI image ever produced, is the foundation of the MRI industry. Dr. Damadian published his discovery in his milestone 1971 paper in the journal Science (Science 171:1151, 1971) and filed the pioneer patent for the practical use of his discovery in 1972.” (www.fonar.com/news/022409.htm).

#

FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)

ASSETS
March 31,
2009
(UNAUDITED)
June 30,
2008
Current Assets:
Cash and cash equivalents
$ 1,605
$ 1,326
Marketable securities
18
1,068
Accounts receivable - net
5,206
4,689
Accounts receivable - related parties - net
619
469
Medical receivables - net
555
1,228
Management fee receivable - net
4,051
5,040
Management fee receivable - related medical practices - net
1,480
1,372
Costs and estimated earnings in excess of billings on uncompleted contracts
528
6
Inventories
3,793
3,256
Current portion of advances and notes to related medical practices
193
214
Current portion of notes receivable less discount for below market interest
509
2,508
Prepaid expenses and other current assets
409
811

Total Current Assets

18,966
21,987
 
----------------
----------------
Property and equipment - net
3,152
3,933
Advances and notes to related medical practices - net
133
263
Notes receivable less discount for below market interest
1,912
2,297
Other intangible assets - net
4,896
4,810
Other assets
574
1,936
 
----------------
----------------
Total Assets
$ 29,633
$ 35,226
 
===========
===========

 

FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
March 31,
2009
(UNAUDITED)
June 30,
2008
Current Liabilities:    
Current portion of long-term debt and capital leases
$ 141
$ 373
Accounts payable
3,720
4,020
Other current liabilities
8,045
8,316
Unearned revenue on service contracts
5,045
4,732
Unearned revenue on service contracts - related parties
612
462
Customer advances
7,871
12,804
Customer advances - related party
854
1,472
Billings in excess of costs and estimated earnings on uncompleted contracts
5,133
5,773
Total Current Liabilities
31,421
37,952
Long-Term Liabilities:    
Due to related medical practices
95
98
Long-term debt and capital leases, less current portion
746
757
Other liabilities
319
497
Total Long-Term Liabilities
1,160
1,352
Total Liabilities
32,581
39,304
Minority interest
64
167
     
STOCKHOLDERS' DEFICIENCY:    
Class A non-voting preferred stock $.0001 par value;
1,600,000 authorized, 313,451 issued and outstanding
at March 31, 2009 and June 30, 2008
-
-

Common Stock $.0001 par value; 30,000,000 shares
authorized at March 31, 2009 and June 30, 2008,
4,915,918 issued at March 31, 2009 and June 30, 2008
4,904,275 outstanding at March 31, 2009 and June 30, 2008

1
1

Class B Common Stock $ .0001 par value; 800,000
shares authorized, (10 votes per share), 158 issued
and outstanding at March 31, 2009 and June 30, 2008

-
-


Class C Common Stock $.0001 par value; 2,000,000 shares
authorized, (25 votes per share), 382,513 issued
and outstanding at March 31, 2009 and June 30, 2008

-
-

Paid-in capital in excess of par value

172,276
172,276
Accumulated other comprehensive loss
( 25)
( 73)
Accumulated deficit
(174,320)
(175,380)
Notes receivable from employee stockholders
( 269)
( 394)
Treasury stock, at cost - 11,643 shares of common stock at March 31, 2009 and June 30, 2008
( 675)
( 675)
 
----------------
----------------

Total Stockholders' Deficiency

( 3,012)
(4,245)

Total Liabilities and Stockholders' Deficiency

$ 29,633
$ 35,226
 
===========
===========

 

FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data)
 
FOR THE THREE MONTHS ENDED
MARCH 31,
REVENUES
2009
2008
Product sales - net
$ 6,156
$2,348
Service and repair fees - net
2,291
2,515
Service and repair fees - related parties - net
331
270
Management and other fees - net
1,736
2,110
Management and other fees - related medical practices-net
742
828
 
----------------
----------------
Total Revenues - Net
11,256
8,071
 
----------------
----------------
COSTS AND EXPENSES    
Costs related to product sales
3,325
2,237
Costs related to service and repair fees
865
1,148
Costs related to service and repair fees - related parties
125
123
Costs related to management and other fees
1,039
1,342
Costs related to management and other fees - related medical practices
686
751
Research and development
872
1,189
Selling, general and administrative
3,219
4,311
Provision (Credit) for bad debts
363
( 309)
 
----------------
----------------
Total Costs and Expenses
10,494
10,792
 
----------------
----------------
Income (Loss) From Operations
762
( 2,721)
     
Interest Expense
( 75)
( 105)
Investment Income
91
156
Interest Income - Related Parties
5
8
Other (Expense) Income
( 17)
1
Minority Interest in Income of Partnerships
-
( 34)
Provision for Income Taxes
( 36)
-
 
----------------
----------------
NET INCOME (LOSS)
$ 730
$( 2,695)
 
===========
===========
Net Income (Loss) Available to Common Stockholders
$ 686
$ (2,695)
 
===========
===========
Basic Net Income (Loss) Per Common Share
$ 0.14
$ (0.55)
 
===========
===========
Diluted Net Income (Loss) Per Common Share
$ 0.13
$ (0.55)
 
===========
===========
Basic and Diluted Income Per Share - Common C
$ 0.04
-
 
===========
===========
Weighted Average Basic Shares Outstanding
4,904,275
4,904,261
 
===========
===========
Weighted Average Diluted Shares Outstanding
5,031,779
4,904,261
 
===========
===========

 

FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data)
 
FOR THE NINE MONTHS ENDED
MARCH 31,
REVENUES
2009
2008
Product sales - net
$ 11,975
$ 8,940
Service and repair fees - net
6,936
7,444
Service and repair fees - related parties - net
966
786
Management and other fees - net
5,518
6,354
Management and other fees - related medical practices-net
2,181
2,739
License fees and royalties
1,755
1,158
 
----------------
----------------
Total Revenues - Net
29,331
27,421
 
----------------
----------------
COSTS AND EXPENSES    
Costs related to product sales
7,590
8,566
Costs related to service and repair fees
2,696
3,546
Costs related to service and repair fees - related parties
376
375
Costs related to management and other fees
3,316
3,898
Costs related to management and other fees - related medical practices
2,040
2,241
Research and development
2,681
3,675
Selling, general and administrative
9,955
15,544
Provision for bad debts
1,063
279
 
----------------
----------------
Total Costs and Expenses
29,717
38,124
 
----------------
----------------
Loss From Operations
( 386)
(10,703)
     
Interest Expense
( 193)
( 362)
Investment Income
236
531
Interest Income - Related Parties
17
27
Other (Expense) Income
( 15)
7
Minority Interest in Income of Partnerships
( 11)
( 208)
Gain on Sale of Investment
-
571
Gain on Sale of Consolidated Subsidiary
1,448
3,395
Provision for Income Taxes
( 36)
-
 
----------------
----------------
NET INCOME (LOSS)
$ 1,060
$ ( 6,742)
 
===========
===========
Net Income (Loss) Available to Common Stockholders
$ 997
$ (6,742)
 
===========
===========
Basic Net Income (Loss) Per Common Share
$ 0.20
$ (1.38)
 
===========
===========
Diluted Net Income (Loss) Per Common Share
$ 0.19
$ (1.38)
 
===========
===========
Basic and Diluted Income per share - Common C
$ 0.05
-
 
===========
===========
Weighted Average Basic Common Shares Outstanding
4,904,275
4,895,907
 
===========
===========
Weighted Average Diluted Common Shares Outstanding
5,031,779
4,895,907
 
===========
===========

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.
###

FONAR™ Corporation
110 Marcus Drive
Melville, N.Y. 11747
Tel. 631-694-2929
Fax. 631-390-9540
Email sales@FONAR.com
Investor Information

top of page

Site Map | Terms of Use-Our Privacy Policy Use
Copyright © 2009 FONAR- All Rights Reserved